News Digest / Ticker: ROG.SW

Ticker: ROG.SW

06:09am, Monday, Nov 10, 2025

Roche's Fenebrutinib Shines in Phase III Trials for Multiple Sclerosis

Roche (SIX:ROG) reveals strong Phase III trial results for fenebrutinib, an oral MS drug that cuts relapse rates and slows disability, potentially addressing both major MS forms.

06:21am, Thursday, Sep 18, 2025

Roche to Tender for 89bio at $14.50 a Share - Pegozafermin Deal Could Hit $3.5B with $6 CVR